Evidence map›Paper›PMID 31161518›Full record

Observational studyInternational urology and nephrology2019

Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study.

Hasan Koc, Hasan Hoser, Yalcin Akdag, Cemaliye Kendir, F Fevzi Ersoy

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in International urology and nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Lactobacillus johnsonii Generates Cyclo(pro-trp) and Promotes Intestinal CaAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  3. Article
  4. Two-way Road of Kidney and Hypercalcemia: A Narrative Review.Cardiovascular & hematological disorders drug targets · 2023
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hasan KocHayat Dialysis Center, Istanbul, Turkey.
Hasan HoserCinar Dialysis Center, Kutahya, Turkey.
Yalcin AkdagLarende Dialysis Center, Karaman, Turkey.
Cemaliye KendirBesyuzevler Safak Hospital, Istanbul, Turkey.
F Fevzi ErsoyDivision of Nephrology, Department of Medicine, Akdeniz University Medical School, Akdeniz University Hospital, Dumlupınar Blv. Konyaaltı, Antalya, Turkey. ersoy@akdeniz.edu.tr.ORCID http://orcid.org/0000-0001-9722-1560
Akdeniz University · TRGöztepe Şafak Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate monthly percentage changes of intact parathyroid hormone (iPTH) and other major bone marker levels in patients with secondary hyperparathyroidism (SHPT) undergoing hemodialysis (HD) and receiving paricalcitol.

methodsA total of 493 (F/M 244/249) adult patients with SHPT who were undergoing HD in 22 HD units and receiving paricalcitol treatment, with iPTH > 300 mg/mL, adjusted serum levels of calcium (Ca) < 10.2 mg/dL, and serum levels of inorganic phosphorus (iP) < 6 mg/dL were included in this multi-center, national, prospective, observational study. Data regarding efficacy, safety, and adverse events of paricalcitol treatment were collected during a 12-month follow-up period through monthly visits along with serum iPTH, Ca, iP, alkaline phosphatase (ALP) and other required biochemistry tests as necessary. Mortality data until 6 months after the end of the study were also investigated.

resultsThe mean age was 58.3 ± 15.8 years and the mean duration of HD was 6.2 ± 5.5 years, respectively. As of 12th month, mean iPTH values decreased from 646 ± 424 pg/mL to 473 ± 387 pg/mL (p < 0.001); no statistically significant changes were observed in Ca levels (p > 0.05). Serum ALP levels also significantly decreased (p = 0.001) and serum phosphorus levels significantly increased (p < 0.001) during the study observation period. Reasons for early terminations were being lost to follow-up (n = 119, 24.1%), hyperphosphatemia (iP > 6 mg/dL, n = 108, 21.9%), low iPTH levels (iPTH < 150 mg/dL, n = 97, 19.7%), and withdrawal of consent (n = 41, 8.3%). In total 32 patients (6.5%) were prematurely terminated the study with hypercalcemia (Ca > 10.2 mg/dL). 46.9% of those hypercalcemic patients had other anomalies with iP and iPTH levels along with hypercalcemia.

conclusionParicalcitol treatment, resulted in successful iPTH control. In approximately 6.5% of the patients paricalcitol treatment was discontinued since Ca levels reached > 10.2 mg/dL in those patients. No unfavorable effects on serum phosphorus and Ca-phosphorus (Ca × P) product were observed.

Indexed as

ErgocalciferolsHyperparathyroidism, SecondaryRenal DialysisBone Density Conservation AgentsCalciumDrug MonitoringFemaleHumansKidney Failure, ChronicMaleMiddle AgedParathyroid HormonePhosphorusProspective StudiesTurkeyBone Density Conservation AgentsCalciumErgocalciferolsParathyroid HormoneparicalcitolPhosphorusChronic kidney diseaseEnd-stage renal diseaseHemodialysisHyperparathyroidismParicalcitol

Identifiers

PMID31161518
OpenAlexW2948885978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.